NCT05408338

Brief Summary

This study will focus on acute effects of added sugars on brain health in a specific age group (30-64 years old). We will provide participants two meals (one meal containing 16 g of added sugars and the other containing 61 g of added sugars) and examine blood vessel function and brain structure using a MRI.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 2, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 7, 2022

Completed
7 days until next milestone

Study Start

First participant enrolled

June 14, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 17, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 17, 2023

Completed
Last Updated

May 10, 2023

Status Verified

May 1, 2023

Enrollment Period

10 months

First QC Date

June 2, 2022

Last Update Submit

May 9, 2023

Conditions

Keywords

added sugarsbrain blood vessel functionbrain structureMRI

Outcome Measures

Primary Outcomes (6)

  • Change from baseline in cerebrovascular reactivity at 3 hours post-consumption of each meal

    % change in total cerebral perfusion measured using pseudo-continuous arterial spin labeling in response to 3-minutes of hypercapnia (+9 mmHg increase in PETCO2)

    Over 2 weeks, at baseline and 3 hours post-consumption of each meal (low and high added sugar), separated by a 1-week washout

  • Change from baseline in hippocampal stiffness after 3 hours post-consumption of each meal

    Magnetic Resonance Elastography (MRE) of the brain to assess hippocampal viscoelastic properties while the head will be vibrated using the Resoundant acoustic driver system

    Over 2 weeks, at baseline and 3 hours post-consumption of each meal (low and high added sugar), separated by a 1-week washout

  • Change from baseline in hippocampal damping ratio at 3 hours post-consumption of each meal

    Magnetic Resonance Elastography (MRE) of the brain to assess hippocampal viscoelastic properties while the head will be vibrated using the Resoundant acoustic driver system

    Over 2 weeks, at baseline and 3 hours post-consumption of each meal (low and high added sugar), separated by a 1-week washout

  • Change from baseline in uric acid at 3 hours post-consumption of each meal

    Blood biomarker of uric acid (e.g. serum uric acid)

    Over 2 weeks, at baseline and 3 hours post-consumption of each meal (low and high added sugar), separated by a 1-week washout

  • Change from baseline in triglycerides at 3 hours post-consumption of each meal

    Blood biomarker of triglycerides (e.g. serum triglycerides)

    Over 2 weeks, at baseline and 3 hours post-consumption of each meal (low and high added sugar), separated by a 1-week washout

  • Change from baseline in oxidative stress at 3 hours post-consumption of each meal

    Blood biomarker of oxidative stress (e.g. superoxide)

    Over 2 weeks, at baseline and 3 hours post-consumption of each meal (low and high added sugar), separated by a 1-week washout

Secondary Outcomes (4)

  • Change from baseline in hippocampal cerebrovascular reactivity at 3 hours post-consumption of each meal

    Over 2 weeks, at baseline and 3 hours post-consumption of each meal (low and high added sugar), separated by a 1-week washout

  • Changes from baseline in resting cerebral blood flow at 3 hours post-consumption of each meal

    Over 2 weeks, at baseline and 3 hours post-consumption of each meal (low and high added sugar), separated by a 1-week washout

  • Change from baseline in other lipid profile at 3 hours post-consumption of each meal

    Over 2 weeks, at baseline and 3 hours post-consumption of each meal (low and high added sugar), separated by a 1-week washout

  • Change from baseline in blood pressure at 3 hours post-consumption of each meal

    Over 2 weeks, at baseline and 3 hours post-consumption of each meal (low and high added sugar), separated by a 1-week washout

Study Arms (2)

Low Added Sugar Meal

EXPERIMENTAL

Participants will be provided a meal low in added sugars.

Other: Low Added Sugar Meal

High Added Sugar Meal

EXPERIMENTAL

Participants will be provided a meal high in added sugars.

Other: High Added Sugar Meal

Interventions

Consumption of a single 1,250 kcal meal containing 16 g of added sugars (5% of total energy)

Low Added Sugar Meal

Consumption of a single 1,250 kcal meal containing 61 g of added sugars (20% of total energy)

High Added Sugar Meal

Eligibility Criteria

Age30 Years - 64 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Ability to provide informed consent;
  • Men and women within the ages of 30-64 years;
  • Habitual added sugar intake of \<150 kcal/day for men and \<100kcal/day for women;
  • No allergies/intolerance to ingredients in the study meal (e.g., nuts, gluten)

You may not qualify if:

  • Blood chemistries indicative of abnormal liver enzymes and renal function;
  • Abnormal blood chemistry marker that is +/-2.5x the upper or lower limit;
  • Chronic clinical diseases (e.g., coronary artery, peripheral artery, or cerebrovascular diseases, diabetes (type 1 and type 2), stages 5-6 chronic kidney disease, chronic obstructive pulmonary disease);
  • Major psychiatric disorder (e.g. schizophrenia, bipolar disorder, major depression within past two years);
  • Neurological or autoimmune conditions affecting cognition (e.g. Parkinson's disease, epilepsy, multiple sclerosis, head trauma with loss of consciousness greater than 30 min, large vessel infarct);
  • Current medication use likely to affect central nervous system functions (e.g. long active benzodiazepines) and lipid-lowering medications (e.g., statins)
  • Conditions which would contra-indicate MRI: implant of pacemakers or pacemaker wires; artificial heart valve; brain aneurysm surgery; middle ear implant; non-removable hearing aid or jewelry; braces; cataract surgery or lens implant; implanted mechanical or electrical device; foreign metallic objects in the body such as bullets, BBs, shrapnel, or metalwork fragments, claustrophobia;
  • Current smoking;
  • Pregnancy or breastfeeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Delaware

Newark, Delaware, 19713, United States

Location

Study Officials

  • Christopher Martens, PhD

    University of Delaware

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 2, 2022

First Posted

June 7, 2022

Study Start

June 14, 2022

Primary Completion

April 17, 2023

Study Completion

April 17, 2023

Last Updated

May 10, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will not share

Locations